52 results found.

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
afatinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
Afatinib

Non-Small Cell Lung Cancer Clinical Trial using Denosumab; Zometa

Amgen - Recruiting 18 years or older.
- A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer.
Denosumab; Zometa

Cancer, Solid Tumor Clinical Trial using MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma.
MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Recurrent Non-small Cell Lung Cancer, or Stage IV Non-small Cell Clinical Trial using cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy.
cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

Non-Small Cell Lung Cancer Clinical Trial using onartuzumab [MetMAb]; erlotinib [Tarceva]; Placebo

Genentech - Recruiting 18 years or older.
- A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease.
onartuzumab [MetMAb]; erlotinib [Tarceva]; Placebo

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A

Genentech - Recruiting 18 years or older.
- A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer.
MPDL3280A

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY.
MPDL3280A; docetaxel

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER.
MPDL3280A

Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Clinical Trial using bavituximab; Docetaxel; Placebo (for bavituximab)

Peregrine Pharmaceuticals - Recruiting 18 years or older.
- SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone as Second-Line Therapy in Patients With Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer.
bavituximab; Docetaxel; Placebo (for bavituximab)

Solid Tumour,, Breast Cancer,, Metastatic Melanoma,, or Non-small Clinical Trial using F16IL2 in combination with paclitaxel

Philogen S.p.A. - Recruiting 18 years or older.
- Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours.
F16IL2 in combination with paclitaxel

Non-small Cell Lung Cancer Metastatic Clinical Trial using Ramucirumab; Placebo; Docetaxel

Eli Lilly and Company - Recruiting 20 years or older.
- A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy.
Ramucirumab; Placebo; Docetaxel

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

AstraZeneca - Recruiting 18 years or older.
- A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1).
Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, or Ad Clinical Trial using AZD6244; Docetaxel

AstraZeneca - Recruiting 20 years or older.
- A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
AZD6244; Docetaxel

Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, or Stage Clinical Trial using counseling intervention; questionnaire administration; quality-of-life assessment

Stanford University - Recruiting N/A or older.
- Intervention Development for Anxiety in Metastatic NSCLC Patients and Their Caregivers.
counseling intervention; questionnaire administration; quality-of-life assessment

Non-small Cell Lung Cancer Metastatic Clinical Trial using carboplatin; paclitaxel; ABP 215; bevacizumab

Amgen - Recruiting 18 years to 80 years.
- A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer.
carboplatin; paclitaxel; ABP 215; bevacizumab

Non Small Cell Lung Cancer Clinical Trial using Pemetrexed and Reolysin (and safety run-in); Pemetrexed; Docetaxel and Reolysin; Docetaxel

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy..
Pemetrexed and Reolysin (and safety run-in); Pemetrexed; Docetaxel and Reolysin; Docetaxel

Non-Small Cell Lunch Cancer Clinical Trial using BKM120; placebo; Carboplatin; Paclitaxel

Novartis - Recruiting 18 years or older.
- A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology.
BKM120; placebo; Carboplatin; Paclitaxel

Cancer Clinical Trial using Dabrafenib; Trametinib

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Dabrafenib; Trametinib

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC).
selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

AstraZeneca - Recruiting 18 years or older.
- A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV).
Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

Squamous Non-small Cell Lung Cancer Clinical Trial using Buparlisib; Buparlisib matching placebo; Docetaxel

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer.
Buparlisib; Buparlisib matching placebo; Docetaxel

Non-small Cell Lung Cancer Clinical Trial using Induction chemotherapy and concurrent radiation; Consolidation: Radiation therapy to metastatic sites

Leo W. Jenkins Cancer Center - Recruiting 18 years or older.
- A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent.
Induction chemotherapy and concurrent radiation; Consolidation: Radiation therapy to metastatic sites

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase IIIb, Open-label Study of Erlotinib (Tarcevar) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (ESSENCE).
erlotinib [Tarceva]

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using MLN8237 and Erlotinib

Fox Chase Cancer Center - Recruiting 18 years or older.
- A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer.
MLN8237 and Erlotinib

Non-Small Cell Lung Cancer Clinical Trial using Custirsen + Docetaxel; Docetaxel

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer.
Custirsen + Docetaxel; Docetaxel

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Open Label Study of Erlotinib (Tarcevar) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations.
erlotinib [Tarceva]

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Efficacy and Safety of erLotinib (Tarcevar ) Therapy in patiEnts With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) , Subtype adEnocarcinoma, Who Have Good performaNce sTatus (PS 0-1) - ELEMENT.

Lung Cancer, or Metastatic Cancer Clinical Trial using computed tomography; 3-dimensional conformal radiation therapy; fludeoxyglucose F 18; radiation therapy treatment planning/simulation

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Prospective Evaluation of PET-CT Scan in Patients With Non-operable or Non-resectable NSCLC Treated by Radical 3-Dimensional Conformal Radiation Therapy.
computed tomography; 3-dimensional conformal radiation therapy; fludeoxyglucose F 18; radiation therapy treatment planning/simulation

Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib.
LY2875358; Erlotinib

Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Ce Clinical Trial using LY3009120 capsule

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer.
LY3009120 capsule

Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, or Metastatic Clinical Trial using Cabazitaxel-XRP6258

University of Alabama at Birmingham - Recruiting 19 years or older.
- Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients.
Cabazitaxel-XRP6258

Non-small Cell Lung Cancer Metastatic Clinical Trial using Erlotinib

National Guard Health Affairs - Recruiting 18 years or older.
- Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME).
Erlotinib

Non-small Cell Lung Cancer Metastatic Clinical Trial using cisplatin, docetaxel

National Guard Health Affairs - Recruiting 18 years or older.
- A Phase II Study of Docetaxel Combined With Cisplatin as the First Line Chemotherapy in Patients With Metastatic Non-small Cell Lung Cancer.
cisplatin, docetaxel

Melanoma, Ovarian Cancer, Renal Cell Cancer, or Non-small Cell Lu Clinical Trial using IDC-G305

Immune Design - Recruiting 18 years to 80 years.
- A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer.
IDC-G305

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using PET/CT

National Cancer Institute, Naples - Recruiting 18 years or older.
- Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of Chemotherapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC).
PET/CT

Non-small Cell Lung Cancer Clinical Trial using MSC2156119J; Gefitinib; Pemetrexed; Cisplatin

Merck KGaA - Recruiting 18 years or older.
- A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare MSC2156119J Combined With Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First-line Gefitinib.
MSC2156119J; Gefitinib; Pemetrexed; Cisplatin

Non-small Cell Lung Cancer Clinical Trial using RTA 408 Capsules

Reata Pharmaceuticals, Inc. - Recruiting 18 years to 75 years.
- An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer.
RTA 408 Capsules

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using Gemcitabine; Pemetrexed; Cisplatin

National Cancer Institute, Naples - Recruiting 70 years or older.
- A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC..
Gemcitabine; Pemetrexed; Cisplatin

EGFR Positive Non-small Cell Lung Cancer Clinical Trial using Dacomitinib (PF-00299804); Gefitinib

SFJ Pharmaceuticals, Inc. - Recruiting 18 years or older.
- ARCHER 1050: A Randomized, Open Label Phase 3 Efficacy and Safety Study Of Dacomitinib (PF-00299804) Vs. Gefitinib For The First-Line Treatment Of Locally Advanced or Metastatic NSCLC In Subjects With EGFR Activating Mutations.
Dacomitinib (PF-00299804); Gefitinib

Non-small-cell Lung Cancer Clinical Trial using Pemetrexed; Bevacizumab

Hellenic Oncology Research Group - Recruiting 18 years or older.
- Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC).
Pemetrexed; Bevacizumab

Non-small-cell Lung Cancer Clinical Trial using Docetaxel; Bevacizumab

Hellenic Oncology Research Group - Recruiting 18 years or older.
- Docetaxel Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC.
Docetaxel; Bevacizumab

Patients Must Have Histologically or Cytologically Confirmed Non- Clinical Trial using Paclitaxel, Carboplatin, Bevacizumab, and Metformin; Paclictaxl, Carboplatin, and Bevcizumab.

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma.
Paclitaxel, Carboplatin, Bevacizumab, and Metformin; Paclictaxl, Carboplatin, and Bevcizumab.

Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, o Clinical Trial using CTLA-4 Antibody; Hypofractionated Radiotherapy

Western Regional Medical Center - Recruiting 18 years or older.
- A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST).
CTLA-4 Antibody; Hypofractionated Radiotherapy

Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Non-small-ce Clinical Trial using MORAb-066

Morphotek - Recruiting 18 years or older.
- A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies.
MORAb-066

Non-small Cell Lung Cancer, Radiation Therapy, Locally Advanced D Clinical Trial using mid-position radiation strategy; ITV

Centre Leon Berard - Recruiting 18 years or older.
- Randomized Phase 2 Study Evaluating the Interest of Mid-position Strategy Versus ITV (Internal Target Volume) Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-resected Non-small Cell Lung Carcinoma (NSCLC)..
mid-position radiation strategy; ITV

NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC Clinical Trial using Gefitinib and Metformin; Gefitinib and placebo

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University - Recruiting 18 years to 75 years.
- A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer.
Gefitinib and Metformin; Gefitinib and placebo

Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer, or S Clinical Trial using Cisplatin; Pemetrexed; Gemcitabine

Western Regional Medical Center - Recruiting 18 years or older.
- Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer.
Cisplatin; Pemetrexed; Gemcitabine

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial

Chonnam National University Hospital - Recruiting 19 years to 80 years.
- Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib.

Non-small Cell Lung Cancer Metastatic, or Small Cell Lung Carcino Clinical Trial using therapeutic interventions

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network.
therapeutic interventions

Non Small Cell Lung Cancer Clinical Trial using carboplatin paclitaxel bevacizumab; Standard treatment plus nitroglycerin

Dutch Society of Physicians for Pulmonology and Tuberculosis - Recruiting 18 years or older.
- A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12.
carboplatin paclitaxel bevacizumab; Standard treatment plus nitroglycerin

Lung Cancer Clinical Trial using erlotinib hydrochloride; stereotactic body radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Trial of Erlotinib (Tarcevar) in Combination With Stereotactic Body Radiation Therapy (SBRT) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
erlotinib hydrochloride; stereotactic body radiation therapy